title: MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML.
abstract: MLLT11, an MLL fusion partner, is a poor prognostic biomarker for paediatric acute myeloid leukaemia (AML), adult normal cytogenetics AML, and adult myelodysplastic syndrome. MLLT11 is highly regulated during haematopoietic progenitor differentiation and development but its regulatory mechanisms have not been defined. In this study, we demonstrate by transfection experiments that MIR29B directly regulates MLLT11 expression in vitro. MIR29B expression level was also inversely related to MLLT11 expression in a cohort of 56 AML patients (P<0·05). AML patients with low MIR29B/elevated MLLT11 expression had poor overall survival (P=0·038). Therefore, MIR29B may be a potential prognostic biomarker for AML patients.
authors.affiliation: University of Colorado Cancer Center, University of Colorado-Denver, Aurora, CO, USA.
authors.forename: Yin
authors.initials: Y
authors.lastname: Xiong
authors.forename: Zejuan
authors.initials: Z
authors.lastname: Li
authors.forename: Min
authors.initials: M
authors.lastname: Ji
authors.forename: Aik-Choon
authors.initials: AC
authors.lastname: Tan
authors.forename: Judson
authors.initials: J
authors.lastname: Bemis
authors.forename: Jove-Victor
authors.initials: JV
authors.lastname: Tse
authors.forename: Gang
authors.initials: G
authors.lastname: Huang
authors.forename: Jino
authors.initials: J
authors.lastname: Park
authors.forename: Chunyan
authors.initials: C
authors.lastname: Ji
authors.forename: Jianjun
authors.initials: J
authors.lastname: Chen
authors.forename: Lynne T
authors.initials: LT
authors.lastname: Bemis
authors.forename: Kevin D
authors.initials: KD
authors.lastname: Bunting
authors.forename: William
authors.initials: W
authors.lastname: Tse
mesh_terms: D014408:Biomarkers, Tumor / Q000096:biosynthesis / Q000502:physiology*; D020869:Gene Expression Profiling / Q000379:methods; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000378:metabolism*; D035683:MicroRNAs / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D009363:Neoplasm Proteins / Q000096:biosynthesis* / Q000235:genetics; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis* / Q000235:genetics; D012334:RNA, Neoplasm / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D016019:Survival Analysis; D014407:Tumor Cells, Cultured
chemical_list: D014408:Biomarkers, Tumor; C532045:MIRN29a microRNA, human; C091736:MLLT11 protein, human; D035683:MicroRNAs; D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D012334:RNA, Neoplasm